COMMUNIQUÉS West-GlobeNewswire

American College of Medical Genetics and Genomics Includes OGM in Latest Edition of Technical Laboratory Standards for Solid Tumor Analysis
22/02/2024
SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that optical genome mapping (OGM) was included for the first time in the American College of Medical Genetics and [...]
Apnimed to Participate in the Upcoming Evercore ISI 2024 Emerging Biotech Conference
22/02/2024
CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and [...]
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
22/02/2024
Company implementing a series of cost-savings measures designed to extend Salarius’ expected cash runway into the first half of 2025 Extended runway supports the generation of additional data from the ongoing Phase 1/2 [...]
FDA Grants Humanitarian Device Exemption Approval to SeaStar Medical’s Selective Cytopheretic Device for Pediatric Acute Kidney Injury
22/02/2024
SCD-PED (Pediatric) is the first FDA-approved product in the Company’s Quelimmune ™ product family DENVER, Feb. 22, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company [...]
ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option
22/02/2024
Neurological diseases, which affect up to 16 million people over 18 years old in the US, are the leading cause of physical and cognitive disability. A growing body of evidence supports that activation of more than one [...]
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer
22/02/2024
BEDFORD, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and [...]
Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement
22/02/2024
BEDFORD, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (Nasdaq:OCUL) (the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development [...]
Intra-Cellular Therapies Reports Fourth Quarter And Full-Year 2023 Financial Results And Provides Corporate Update
22/02/2024
Full year 2023 total revenues of $464.4 million , compared to $250.3 million in 2022 Full year 2023 CAPLYTA net product sales were $462.2 million , representing year-over-year growth of 86% . CAPLYTA fourth quarter 2023 [...]
Venus Concept Announces CE Mark for Venus Versa Pro in Europe
22/02/2024
TORONTO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received the CE Mark from DEKRA [...]
Kura Oncology to Participate in Three Upcoming Investor Conferences
22/02/2024
SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today [...]
Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
22/02/2024
WAKIX® (pitolisant) Net Revenue of $168.4 Million for Fourth Quarter and $582.0 Million for Full Year 2023; Representing Growth of ~31% and ~33%, Respectively U.S. Food and Drug Administration (FDA) Granted Priority [...]
Ocular Therapeutix™ Announces Board of Directors and Leadership Updates
22/02/2024
Industry Leader and Retina Expert, Pravin U. Dugel, MD, Becomes Executive Chair Jeffrey S. Heier, MD to become Chief Scientific Officer, Peter K. Kaiser, MD to be Medical Director, and Sanjay Nayak, MBBS, PhD to become [...]
Bitech Technologies Appoints Sid Sung as Its New Chief Innovation Officer to Lead the Digital Revolution in the Renewable Energy Industry
22/02/2024
Newport Beach, CA, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bitech Technologies Corporation [ OTCQB: BTTC ], (“the Company” or “Bitech”) a global technology solution provider dedicated to green energy solutions, is delighted [...]
BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
22/02/2024
- Submitted New Drug Application (NDA) to US Food and Drug Administration (FDA) for acoramidis for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) based on positive results of Phase 3 ATTRibute-CM trial [...]
Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024
22/02/2024
WEST CHESTER, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring [...]
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress
22/02/2024
On track to dose the first patient in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy in Q1 2024 Expect to initiate the Phase 3 study of NTLA-2002 for [...]
InflaRx Appoints Jan Medina as Head of Investor Relations
22/02/2024
JENA, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the appointment of [...]
The Joint Corp. to Host Conference Call on Thursday, March 7th to Discuss Fourth Quarter and Year-end 2023 Results
22/02/2024
SCOTTSDALE, Ariz., Feb. 22, 2024 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), the nation's largest provider of chiropractic care through The Joint Chiropractic ® network, announced it will report its fourth [...]
Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan
22/02/2024
-- Supplemental cohort of 12 Japanese patients to be added to global Phase 3 hypothalamic obesity trial, with dosing expected to begin in third quarter of 2024 -- -- Significant unmet need with 5,000 to 8,000 patients [...]

Pages